Client news

A&O Shearman support GSK on the establishment of the GSK-Oxford Cancer Immuno-Prevention Programme

A&O Shearman support GSK on the establishment of the GSK-Oxford Cancer Immuno-Prevention Programme
Published Date
Mar 13 2025

A&O Shearman is advising GSK on its research collaboration with the University of Oxford focused on the potential of cancer prevention through vaccination.

Under the GSK-Oxford Cancer Immuno-Prevention Programme, GSK and the University of Oxford will explore precancer biology to generate key insights on how cancer develops in humans, with the aim to inform new approaches to cancer vaccination. GSK will invest up to GBP50 million over a minimum of three years.

The A&O Shearman team was led by IP transactions partner Nigel Parker and IP transactions senior associate Megan McMellon.

It was great to work with GSK on this research collaboration. The application of vaccines to prevention of cancer is an area with huge potential

Headshot of Nigel Parker

Nigel Parker

Partner

Related capabilities